Kryxana Drug Interactions

Drugs That May Increase Ribociclib Plasma Concentrations: CYP3A4 Inhibitors: Coadministration of strong CYP3A inhibitors increases ribociclib exposure [see Pharmacology: Pharmacokinetics under Actions]. Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation [see QT Interval Prolongation under Precautions]. Avoid concomitant use of strong CYP3A inhibitors with KRYXANA and consider alternative concomitant medications with less potential for CYP3A inhibition.
In patients with advanced or metastatic breast cancer, if coadministration of KRYXANA with a strong CYP3A inhibitor cannot be avoided, reduce the dose of KRYXANA to 400 mg once daily [see Dose Modifications under Dosage & Administration].
Drugs That May Decrease Ribociclib Plasma Concentrations: CYP3A4 Inducers: Coadministration of strong CYP3A4 inducers decreases the plasma exposure of ribociclib [see Pharmacology: Pharmacokinetics under Actions]. Avoid concomitant use of strong CYP3A inducers and consider an alternate concomitant medication with no or minimal potential to induce CYP3A.
Effect of KRYXANA on Other Drugs: CYP3A Substrates: Coadministration of sensitive CYP3A4 substrates with multiple doses of KRYXANA increases the substrate exposure [see Pharmacology: Pharmacokinetics under Actions]. For CYP3A substrates where minimal increases in the concentration may increase CYP3A substrate adverse reactions, monitor for increased adverse reactions of the CYP3A substrate during treatment with KRYXANA. The dose of the sensitive CYP3A substrate may need to be reduced as KRYXANA can increase its exposure.
Drugs That Prolong the QT Interval: Avoid coadministration of KRYXANA with products with a known potential to prolong QT interval, such as antiarrhythmic drugs and other drugs that are known to prolong the QT interval. If concomitant use cannot be avoided, monitor ECG when initiating, during concomitant use, and as clinically indicated [see QT Interval Prolongation under Precautions and Pharmacology: Pharmacodynamics under Actions].